National News
AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
02.19.2019
Endorsement complements the company’s ongoing commitment to physician
education
MASON, Ohio--(BUSINESS WIRE)--Feb. 19, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment
for atrial fibrillation (Afib) and left atrial appendage management,
today announced that The Society of Thoracic Surgeons (STS) has endorsed
its Advanced Ablation course for both physicians and fellows. The course
provides surgeons and other medical professionals with a comprehensive
overview of the treatment of Afib during cardiac surgery.
Founded in 1964, STS is a not-for-profit organization representing more
tha...AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
02.12.2019
cryoSPHERE probe launched in United States, designed exclusively for
post-operative pain block
MASON, Ohio--(BUSINESS WIRE)--Feb. 12, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management (LAAM),
today announced that it has launched the cryoICE® cryoSPHERE™
probe in the United States. The cryoSPHERE probe is the first device in
the cryoICE family solely dedicated to blocking pain by temporarily
ablating peripheral nerves.
The cryoSPHERE probe offers a unique 8mm ball-tip design, a bendable
distal shaft, and an ergonomic handle...AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
02.05.2019
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE®
Ablation System for the treatment of persistent and long-standing
persistent atrial fibrillation in open concomitant cardiac surgery
MASON, Ohio--(BUSINESS WIRE)--Feb. 5, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment
for atrial fibrillation (Afib) and left atrial appendage management,
today announced the first patient was treated in the ICE-AFIB™ trial
(NCT03732794). Following Investigational Device Exemption (IDE) approval
by the FDA, the first patient was treated by Dr. Niv Ad, at Washington
Adventist Hospital in Takoma...AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results
02.04.2019
MASON, Ohio--(BUSINESS WIRE)--Feb. 4, 2019--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its fourth quarter and full year 2018 financial results
on Thursday, February 28, 2019.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, February 28, 2019 to discuss its fourth quarter and full year
2018 financial results. The call may be accessed through an operator by
calling (844) 884-9951 for domestic callers and (661) 378-9661 for
international callers using ...AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018
01.07.2019
MASON, Ohio--(BUSINESS WIRE)--Jan. 7, 2019--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced preliminary financial results for the fourth quarter and
full year 2018 and provided 2019 financial guidance.
Preliminary, unaudited revenue for fourth quarter 2018 is expected to be
approximately $52.9 million, reflecting growth of approximately 15% over
the fourth quarter of 2017. Based on this preliminary estimate, revenue
from U.S. customers is expected to be $43.1 million, reflecting growth
of 19% and driven again by st...AtriCure to Present at the 37th Annual J.P. Morgan Healthcare Conference
12.13.2018
MASON, Ohio--(BUSINESS WIRE)--Dec. 13, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the 37th Annual J.P. Morgan
Healthcare Conference in San Francisco on Monday, January 7, 2019.
Management is scheduled to present at 12:00 p.m. Pacific Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference
11.08.2018
MASON, Ohio--(BUSINESS WIRE)--Nov. 8, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Piper Jaffray 30th
Annual Healthcare Conference in New York City on Wednesday, November 28.
Management is scheduled to present at 8:00 a.m. Eastern Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure Reports Third Quarter 2018 Financial Results
11.01.2018
Worldwide revenue of $49.9 million – an increase of 18.5% year over
year
U.S. revenue of $39.8 million – an increase of 19.1% year over year
International revenue of $10.2 million – an increase of 16.2% year
over year
MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced third
quarter 2018 financial results.
“We are pleased with our third quarter performance and building track
record of strong, consistent,...AtriCure to Participate in Upcoming Investor Conferences
10.22.2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will be participating in upcoming investor conferences.
AtriCure is scheduled to present at the Stifel 2018 Healthcare
Conference in New York City on Wednesday, November 14, 2018. Management
is scheduled to present at 1:15 p.m. Eastern Time. A live audio webcast
of the presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com.
A replay of th...AtriCure to Announce Third Quarter 2018 Financial Results
10.11.2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 11, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its third quarter 2018 financial results on Thursday,
November 1, 2018.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, November 1, 2018 to discuss its third quarter 2018 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 9799908. A...AtriCure Announces Pricing of Public Offering of Common Stock
10.04.2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2018--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced the pricing of its underwritten offering of 2.5 million
shares of its common stock at a price to the public of $30.75 per share
pursuant to its existing shelf registration statement. Net proceeds to
AtriCure from the offering are expected to be approximately $72 million,
after deducting underwriting discounts and commissions and estimated
offering expenses. AtriCure has granted to the underwriters of the
offering a 30-day option to ...AtriCure Reports Preliminary Financial Results for Third Quarter 2018
10.03.2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
preliminary financial results for the third quarter of 2018.
Preliminary and unaudited revenue for the third quarter of 2018 is
expected to be approximately $49.9 million, reflecting growth of
approximately 18.5% over the third quarter of 2017 (18.6% on a constant
currency basis). Based on this preliminary estimate, U.S. revenue is
expected to be approximately $39.8 million, reflecting growth of 19.1%
over the ...AtriCure Announces Proposed Public Offering of Common Stock
10.03.2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced it has commenced an underwritten public offering of 2.5
million shares of its common stock pursuant to its existing shelf
registration statement. In connection with this offering, AtriCure plans
to grant the underwriters of the offering a 30-day option to purchase up
to 375,000 additional shares of common stock at the public offering
price less the underwriting discount. AtriCure intends to use the net
proceeds from the offering for...AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
08.28.2018
Landmark study is the first prospective, randomized study comparing
the Convergent approach to endocardial catheter ablation in persistent
and long-standing persistent atrial fibrillation patients
MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has completed enrollment of the full
cohort of 153 patients in the CONVERGE IDE clinical trial.
The CONVERGE IDE trial is a landmark prospective, randomized trial
underway in the United States comparing the Convergent ap...AtriCure to Present at the Morgan Stanley Global Healthcare Conference
08.21.2018
MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will present at the Morgan Stanley Global Healthcare Conference at
the Grand Hyatt Hotel in New York on Friday, September 14, 2018.
Management is scheduled to present at 1:00 p.m. Eastern Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
presen...AtriCure Reports Second Quarter 2018 Financial Results
08.01.2018
Updates 2018 Financial Outlook
Worldwide revenue of $51.8 million – an increase of 14.5% year over
year
U.S. revenue of $40.8 million – an increase of 14.9% year over year
International revenue of $11.0 million – an increase of 13.1% year
over year
Positive adjusted EBITDA of $0.8 million
MASON, Ohio--(BUSINESS WIRE)--Aug. 1, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
second quarter 2018 financial results...AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
07.16.2018
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Canaccord Genuity 38th
Annual Growth Conference at the Intercontinental Hotel in Boston
on Thursday, August 9, 2018. Management is scheduled to present at 12:00
p.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at ir.atricure.com.
A replay of the presentation will be available for 90 days follo...AtriCure to Announce Second Quarter 2018 Financial Results
07.11.2018
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its second quarter 2018 financial results on Wednesday,
August 1, 2018.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Wednesday, August 1, 2018 to discuss its second quarter 2018 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 1519128. A...AtriCure Announces 2018 Analyst and Investor Meeting
06.12.2018
MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, will host an analyst
and institutional investor meeting on Tuesday, June 26, 2018, in New
York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The
meeting will focus on clinician guest speakers to provide expert
perspectives on broad trends in cardiac surgery and electrophysiology,
key clinical trials, and the collaboration between physicians to best
treat Afib.
Featured speakers:
Marc G...AtriCure Reports First Quarter 2018 Financial Results
04.26.2018
Worldwide revenue of $47.0 million – an increase of 13.9% year over
year
U.S. revenue of $38.4 million – an increase of 15.5% year over year
International revenue of $8.6 million – an increase of 6.9% year over
year
MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced first
quarter 2018 financial results.
“We are pleased with our first quarter performance and meaningful
progress toward completing enrollm...AtriCure to Announce First Quarter 2018 Financial Results
04.05.2018
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its first quarter 2018 financial results on Thursday,
April 26, 2018.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, April 26, 2018 to discuss its first quarter 2018 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 1288126. A live...AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
03.15.2018
MASON, Ohio--(BUSINESS WIRE)--Mar. 15, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Needham & Company’s 17th
Annual Healthcare Conference at the Westin Grand Central in New York on
Tuesday, March 27, 2018. Management is scheduled to present at 1:30 p.m.
Eastern Time. A live audio webcast of the presentation may be accessed
by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days followin...AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
02.26.2018
2017 worldwide revenue of $174.7 million – an increase of 12.6% year
over year
2017 U.S. revenue of $138.4 million – an increase of 13.1% year over
year
2017 international revenue of $36.3 million – an increase of 11.0%
year over year
MASON, Ohio--(BUSINESS WIRE)--Feb. 26, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
fourth quarter and full year 2017 financial results.
“We realized several accomplishments in 2017 underpinned by our
...AtriCure Launches the AtriClip® FLEX•V™ Device in the United States
02.22.2018
New device builds on the “V” clip technology, offering increased
flexibility in left atrial appendage management
MASON, Ohio--(BUSINESS WIRE)--Feb. 22, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management (LAAM), today announced that
it has launched the AtriClip FLEX•V™ Left Atrial Appendage (LAA)
Exclusion System in the United States. The new AtriClip FLEX•V is the
first device of the AtriClip family to offer a clip deployment trigger
release. The device also offers an open-ended AtriClip design combined
with a tip-first clos...AtriCure Names Scott Drake Board Chairman
02.20.2018
Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the
Board of Directors in May
MASON, Ohio--(BUSINESS WIRE)--Feb. 20, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced that Scott Drake has been named Board Chairman, effective at
the annual meeting in May of this year. Concurrent with this
appointment, Richard Johnston, the company’s current chairman, and
Elizabeth D. Krell, Ph.D. are planning to retire from the Board of
Directors and are not standing for re-election.
...AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results
02.07.2018
MASON, Ohio--(BUSINESS WIRE)--Feb. 7, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its fourth quarter and full year 2017 financial results
on Monday, February 26, 2018.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Monday, February 26, 2018 to discuss its fourth quarter and full year
2017 financial results. The call may be accessed through an operator by
calling (844) 884-9951 for domestic callers and (661) 378-9661 for
international callers using conf...AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017
01.08.2018
MASON, Ohio--(BUSINESS WIRE)--Jan. 8, 2018--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
preliminary financial results for the fourth quarter and full year 2017
and provided 2018 financial guidance.
Preliminary and unaudited revenue for fourth quarter 2017 is expected to
be approximately $46.1 million, reflecting growth of approximately 12%
over the fourth quarter of 2016. Based on this preliminary estimate,
revenue from U.S. customers is expected to be $36.2 million, reflecting
growth of 11% and r...AtriCure to Present at the 36th Annual JP Morgan Healthcare Conference
12.14.2017
MASON, Ohio--(BUSINESS WIRE)--Dec. 14, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the 36th Annual JP Morgan
Healthcare Conference at the Westin St. Francis Hotel in San Francisco
on Monday, January 8, 2018. Management is scheduled to present at 12:00
p.m. Pacific Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at ir.atricure.com.
A replay of the presentation will be available for 90 days f...AtriCure to Present at the Piper Jaffray 29th Annual Healthcare Conference
11.09.2017
MASON, Ohio--(BUSINESS WIRE)--Nov. 9, 2017--
AtriCure,
Inc. (Nasdaq:ATRC),
a leading innovator in surgical treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will present at the Piper Jaffray 29th Annual Healthcare
Conference at the Palace Hotel in New York on Tuesday, November 28,
2017. Management is scheduled to present at 9:30 a.m. Eastern Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
...AtriCure Reports Third Quarter 2017 Financial Results
11.01.2017
Worldwide revenue of $42.2 million – an increase of 9.9% year over
year
U.S. revenue of $33.4 million – an increase of 9.2% year over year
International revenue of $8.8 million – an increase of 12.8% year
over year
MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced third
quarter 2017 financial results.
“Our third quarter was marked by several accomplishments, and our
revenue results reflect mixed perfor...AtriCure to Present at the Stifel Healthcare Conference
10.20.2017
MASON, Ohio--(BUSINESS WIRE)--Oct. 20, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Stifel Healthcare Conference at
the Palace Hotel in New York on Tuesday, November 14, 2017. Management
is scheduled to present at 4:15 p.m. Eastern Time. A live audio webcast
of the presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure to Announce Third Quarter 2017 Financial Results
10.10.2017
MASON, Ohio--(BUSINESS WIRE)--Oct. 10, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its third quarter 2017 financial results on Wednesday,
November 1, 2017.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Wednesday, November 1, 2017 to discuss its third quarter 2017 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 66481143...AtriCure Announces U.S. Launch of the AtriClip® PRO•V™ Device
09.12.2017
Open-ended AtriClip design, along with smaller profile, allows for
greater flexibility in minimally-invasive therapies
MASON, Ohio--(BUSINESS WIRE)--Sep. 12, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion
System in the United States. The new device offers an open-ended design
combined with a tip-first closure mechanism to enable easier navigation
and placement when operating in minimally-invasive surgery (MIS)
environments. Th...AtriCure to Present at the Morgan Stanley Global Healthcare Conference
08.18.2017
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Morgan Stanley Global Healthcare
Conference at the Grand Hyatt in New York on Tuesday, September 12,
2017. Management is scheduled to present at 5:15 p.m. Eastern Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 180 days following
the p...AtriCure Reports Second Quarter 2017 Financial Results
07.27.2017
Worldwide revenue of $45.2 million – an increase of 14.0% year
over year
U.S. revenue of $35.5 million – an increase of 15.1% year over
year
International revenue of $9.7 million – an increase of 10.2%
year over year
MASON, Ohio--(BUSINESS WIRE)--Jul. 27, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
second quarter 2017 financial results.
“We are executing on our strategy to deliver solid, balanced, results
across our business...AtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference
07.20.2017
MASON, Ohio--(BUSINESS WIRE)--Jul. 20, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the Canaccord Genuity 37th
Annual Growth Conference at the Intercontinental Hotel in Boston on
Thursday, August 10, 2017. Management is scheduled to present at 1:00
p.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at ir.atricure.com.
A replay of the presentation will be available for 90 days follo...AtriCure Announces Hiring of Chief Technology Officer
07.18.2017
MASON, Ohio--(BUSINESS WIRE)--Jul. 18, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has hired Salvatore (Sam) Privitera as
its Chief Technology Officer. Mr. Privitera will have responsibility for
Research and Development activities, as well as Operations, including
manufacturing, supply chain, and quality systems.
Most recently, Mr. Privitera served as Vice President of Research and
Development at Bard Medical (“BMD”), a division of C.R. Bard (NYSE:
BCR), where he helped grow BMD approximately 40% in...AtriCure to Announce Second Quarter 2017 Financial Results
07.06.2017
MASON, Ohio--(BUSINESS WIRE)--Jul. 6, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its second quarter 2017 financial results on Thursday,
July 27, 2017.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, July 27, 2017 to discuss its second quarter 2017 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 46656278. A liv...AtriCure to Present at the JMP Securities Life Science Conference
05.18.2017
MASON, Ohio--(BUSINESS WIRE)--May 18, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will present at the JMP Securities Life Science
Conference at the St. Regis Hotel in New York City on Tuesday, June 20,
2017. Management is scheduled to present at 3:30 p.m. Eastern Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
pres...AtriCure Reports First Quarter 2017 Financial Results
05.04.2017
Worldwide revenue of $41.3 million – an increase of 14.8% year over
year
U.S. revenue of $33.3 million – an increase of 17.7% year over year
International revenue of $8.0 million – an increase 4.4% year over year
MASON, Ohio--(BUSINESS WIRE)--May 4, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced first
quarter 2017 financial results.
“During the first quarter of 2017, we made significant progress across
our strategic priorities, achieving solid r...AtriCure to Announce First Quarter 2017 Financial Results
04.07.2017
MASON, Ohio--(BUSINESS WIRE)--Apr. 7, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its first quarter 2017 financial results on Thursday,
May 4, 2017.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, May 4, 2017 to discuss its first quarter 2017 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 45359788. A live audi...AtriCure Names Two New Members to its Board of Directors
03.21.2017
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced that Regina Groves and B. Kristine Johnson have been appointed
to its Board of Directors. In addition, the company announced that
Michael Hooven and Karen Robards, two existing members of the Board of
Directors, will not stand for re-election.
Ms. Groves has been the Chief Executive Officer at REVA Medical, Inc.
(ASX: RVA), since September of 2015. Prior to her current position, Ms.
Groves served as Vice Pr...AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
03.14.2017
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced that it has named Dr. David B. DeLurgio as
the national principal investigator (PI) for the CONVERGE IDE clinical
trial.
Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in
Atlanta, GA. He is Director of Electrophysiology at the Emory Heart and
Vascular Center at Emory St. Joseph’s Hospital, a role he has served in
since 2014. Dr. DeLurgio earned his medical degree from the University
of Californi...AtriCure to Present at the Needham & Company’s 16th Annual Healthcare Conference
03.10.2017
MASON, Ohio--(BUSINESS WIRE)--Mar. 10, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will present at the Needham & Company’s 16th Annual
Healthcare Conference at the Westin Grand Central Hotel in New York City
on Tuesday, April 4, 2017. Management is scheduled to present at 10:00
a.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at ir.atricure.com.
A replay of the presentation will be available for 90 days...AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
03.06.2017
MASON, Ohio--(BUSINESS WIRE)--Mar. 6, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD
as its Senior Vice President of Clinical, Regulatory, and Scientific
Affairs.
Most recently, Dr. Doraiswamy served as Vice President of Global
Clinical Operations at St. Jude Medical. In his role he oversaw clinical
operations for over 100 clinical trials across the world, and managed a
team of over 300 people. During his time at St. Jude Medical, he led the
integration o...AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results
02.28.2017
2016 revenue of $155.1 million – up 19.5%
2016 U.S. sales of $122.4 million – up 19.7%
2016 International sales of $32.7 million – up 18.8%
MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
fourth quarter and full year 2016 financial results.
“As we reflect back on 2016, we are pleased to have grown revenue 20%
for the year while exceeding our bottom line expectations and making
meaningful progress in continuing...AtriCure to Announce Fourth Quarter and Full Year 2016 Financial Results
02.03.2017
MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will release its fourth quarter and full year 2016 financial results
on Tuesday, February 28, 2017.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, February 28, 2017 to discuss its fourth quarter and full year
2016 financial results. The call may be accessed through an operator by
calling (844) 884-9951 for domestic callers and (661) 378-9661 for
international callers using confer...AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016
02.03.2017
MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
preliminary financial results for the fourth quarter and full year 2016
and provided 2017 financial guidance.
Preliminary and unaudited revenue for fourth quarter 2016 is expected to
be approximately $41.2 million, reflecting growth of approximately 15%
over the fourth quarter of 2015. Based on this preliminary estimate,
revenue from U.S. customers is expected to be $32.7 million, reflecting
growth of 13%. Expe...AtriCure to Present at the Leerink Partners Global Healthcare Conference
01.24.2017
MASON, Ohio--(BUSINESS WIRE)--Jan. 24, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it will present at the Leerink Partners Global Healthcare Conference at
the Palace Hotel in New York City on Thursday, February 16, 2017.
Management is scheduled to present at 9:30 a.m. Eastern Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
pre...AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016
01.09.2017
MASON, Ohio--(BUSINESS WIRE)--Jan. 9, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced
preliminary financial results for the fourth quarter and full year 2016
and provided 2017 financial guidance.
Preliminary and unaudited revenue for fourth quarter 2016 is expected to
be approximately $41.2 million, reflecting growth of approximately 15%
over the fourth quarter of 2015. Based on this preliminary estimate,
revenue from U.S. customers is expected to be $32.7 million, reflecting
growth of 13%. Expe...AtriCure to Present at the 35th Annual JP Morgan Healthcare Conference
12.15.2016
MASON, Ohio--(BUSINESS WIRE)--Dec. 15, 2016--
AtriCure,
Inc. (Nasdaq:ATRC),
a leading innovator in treatments for atrial fibrillation (Afib) and
left atrial appendage (LAA) management, today announced that it will
present at the 35th Annual JP Morgan Healthcare Conference at
the Westin St. Francis Hotel in San Francisco on Thursday, January 12,
2017. Management is scheduled to present at 9:30 a.m. Pacific Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
...AtriCure Names Sven Wehrwein to its Board of Directors
11.11.2016
MASON, Ohio--(BUSINESS WIRE)--Nov. 11, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
Sven Wehrwein has been appointed to its Board of Directors.
Mr. Wehrwein has been an independent financial consultant to emerging
companies since 1999. He has more than 35 years of experience as an
investment banker, chief financial officer, and certified public
accountant. Wehrwein currently sits on the boards of several companies,
including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has
ser...AtriCure to Present at the Piper Jaffray 28th Annual Healthcare Conference
11.07.2016
MASON, Ohio--(BUSINESS WIRE)--Nov. 7, 2016--
AtriCure,
Inc. (Nasdaq:ATRC),
a leading innovator in treatments for atrial fibrillation (Afib) and
left atrial appendage (LAA) management, today announced that it will
present at the Piper Jaffray 28th Annual Healthcare
Conference at the Lotte New York Palace Hotel in New York City on
Wednesday, November 30, 2016. Management is scheduled to present
at 11:30 a.m. Eastern Time. A live audio webcast of the presentation may
be accessed by visiting the Investors page of AtriCure’s corporate
website at www.atricure.com.
A replay of the presentation will be available for 90 days...AtriCure Announces Approval for the cryoICE™ Platform in Japan
11.01.2016
Approval adds to the growing portfolio of AtriCure products now
available in the Japanese market
MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it has received approval from the Japanese Ministry of Health, Labor and
Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation probe.
The approval marks the first time that these products will be available
in the Japanese market.
“We are pleased to have this approval in hand, and to be able to bri...AtriCure Reports Third Quarter 2016 Financial Results
10.27.2016
Revenue of $38.3 million – up 22.0%
U.S. sales of $30.6 million – up 24.0%
International sales of $7.8 million – up 14.9%
MASON, Ohio--(BUSINESS WIRE)--Oct. 27, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced third quarter 2016 financial results.
“We are pleased to report solid third quarter results led by sales in
the U.S. and driven by all areas of our business,” said Mike Carrel,
President and Chief Executive Officer of AtriCure. “Our focus on
improvin...AtriCure Announces Upcoming Investor Conference Schedule
10.24.2016
MASON, Ohio--(BUSINESS WIRE)--Oct. 24, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced that it will present at the Stifel Healthcare Conference
at the Lotte New York Palace Hotel in New York City on Tuesday, November
15, 2016. Management is scheduled to present at 9:30 a.m. Eastern Time.
A live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure to Announce Third Quarter 2016 Financial Results
10.04.2016
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2016--
AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the third quarter of 2016 on Thursday,
October 27, 2016.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, October 27, 2016 to discuss its third quarter 2016 financial
results. The call may be accessed through an operator by calling (844)
884-9951 for domestic callers and (661) 378-9661 for international
callers using conference ID number 91346855. A live webcast of the
confer...AtriCure to Present at the Morgan Stanley Global Healthcare Conference
08.18.2016
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced that it will present at the Morgan Stanley Global
Healthcare Conference at the Grand Hyatt Hotel in New York City on
Wednesday, September 14, 2016. Management is scheduled to present
at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may
be accessed by visiting the Investors page of AtriCure’s corporate
website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
pre...AtriCure Reports Second Quarter 2016 Financial Results
08.04.2016
Revenue of $39.7 million – up 21.8% as reported, 21.5% constant
currency
U.S. sales of $30.9 million – up 19.9%
International sales of $8.8 million – up 28.7% as reported, 27.4%
constant currency
MASON, Ohio--(BUSINESS WIRE)--Aug. 4, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced second quarter 2016 financial results.
“We are pleased to report second quarter results which reflect many
accomplishments – we launched two new products, made progress with...AtriCure to Present at the Canaccord Genuity Growth Conference
07.22.2016
MASON, Ohio--(BUSINESS WIRE)--Jul. 22, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the Canaccord Genuity Growth
Conference at the Intercontinental Hotel in Boston on Wednesday, August
10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time.
A live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
A...AtriCure to Announce Second Quarter 2016 Financial Results
07.11.2016
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the second quarter of 2016 on
Thursday, August 4, 2016.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, August 4, 2016 to discuss its second quarter 2016 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (855)
...AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
06.21.2016
FROST will evaluate cryoablation of peripheral nerves for the
temporary management of post-operative pain
MASON, Ohio--(BUSINESS WIRE)--Jun. 21, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced the first patient has been enrolled in the FROST study at
William Beaumont Hospital, Dearborn, MI. This company-sponsored trial
will evaluate intraoperative cryoanalgesia therapy using cryoablation in
conjunction with standard of care (SOC) pain management compared to SOC
alone.
The design of...AtriCure to Present at the UBS Global Healthcare Conference
05.02.2016
MASON, Ohio--(BUSINESS WIRE)--May 2, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the UBS Global Healthcare Conference
at the Grand Hyatt in New York on Monday, May 23, 2016. Management is
scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of
the presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
About AtriCure, Inc....AtriCure Reports First Quarter 2016 Financial Results
04.28.2016
Revenue of $35.9 million – up 20.3% as reported, 20.4% constant
currency
U.S. sales of $28.3 million – up 23.3%
International sales of $7.7 million – up 10.1% as reported, 10.9%
constant currency
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced first quarter 2016 financial results.
“We are pleased to report first quarter results which reflect solid
operational and commercial execution. Performance in the quarter was
...AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
04.28.2016
MASON, Ohio--(BUSINESS WIRE)--Apr. 28, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it has entered into an amended and restated term loan and
revolving line of credit agreement with Silicon Valley Bank, providing
access to a new $25 million five-year term loan, as well as renewing a
$15 million revolving line of credit.
"We are pleased to have Silicon Valley Bank as a partner," said Andy
Wade, Senior Vice President and Chief Financial Officer of AtriCure.
"This loan facility strengthens our balance sheet an...AtriCure Receives FDA Clearance for New AtriClip® Device
04.26.2016
AtriClip PRO2™ LAA Exclusion System features a
streamlined hoopless end effector
MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced U.S. Food
and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2
Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2
system has increased functionality which enhances the capability to
occlude the LAA during minimally-invasive surgical (MIS) procedures.
“We are excited to receive FDA clearance for the A...AtriCure Announces 510(k) Clearance for the cryoFORM™ Cryoablation Probe
04.12.2016
Clearance brings an even more flexible probe to the U.S. market for
use in a variety of surgical interventions to treat cardiac arrhythmias;
product was launched in Europe in October 2015
MASON, Ohio--(BUSINESS WIRE)--Apr. 12, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
received 510(k) clearance for the cryoFORM cryoablation probe, which
offers increased probe flexibility to adapt to a variety of surgical
ablation procedures. The probe was previously launched in October 2015
in the Europea...AtriCure to Announce First Quarter 2016 Financial Results
04.05.2016
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the first quarter of 2016 on Thursday,
April 28, 2016.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, April 28, 2016 to discuss its first quarter 2016 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (855)
3...AtriCure Reports Fourth Quarter and Full Year 2015 Financial Results
02.23.2016
2015 revenue of $129.8 million – up 20.8% as reported, 23.8% constant
currency
2015 U.S. sales of $102.2 million – up 27.4%
Fourth quarter 2015 revenue of $35.9 million – up 21.9% as reported,
24.0% constant currency
MASON, Ohio--(BUSINESS WIRE)--Feb. 23, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced fourth quarter and full year 2015 financial results.
“We are pleased to report strong 2015 results, positioning us well in
2016 as we continue to execute on ...AtriCure Enrolls First Patient in Randomized Multi-Center Trial Evaluating Post-Operative Afib
02.17.2016
This study will evaluate the effects of excluding the LAA in cardiac
surgery patients at high risk of developing post-operative Afib
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 17, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, announced today that the
first patient was enrolled and treated at PinnacleHealth Hospitals in
Harrisburg, Pennsylvania in the ATLAS (AtriClip®
Left Atrial Appendage
Exclusion Concomitant to Structural Heart
Procedures) clinical study. This observational study explores the use of
the AtriCli...AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
02.01.2016
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 1, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the fourth quarter and full year 2015
on Tuesday, February 23, 2016.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, February 23, 2016 to discuss its fourth quarter and full year
2015 financial results. A live webcast of the conference call will be
available online on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through...AtriCure to Present at the Leerink Global Healthcare Conference
01.21.2016
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 21, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the Leerink Global Healthcare
Conference at the Waldorf Astoria Hotel in New York on Thursday,
February 11, 2016. Management is scheduled to present at 8:05 a.m.
Eastern Time. A live audio webcast of the presentation may be accessed
by visiting the Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance
01.11.2016
MASON, Ohio--(BUSINESS WIRE)--Jan. 11, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced preliminary financial results for fourth quarter and full year
2015 and updated 2016 financial guidance.
Preliminary and unaudited revenue for fourth quarter 2015 is expected to
be approximately $35.9 million, reflecting growth of approximately 21.9%
over the fourth quarter of 2014. Based on this preliminary estimate,
revenue from U.S. customers is expected to be $28.9 million, reflecting
growth of 30.7%, and revenue from interna...AtriCure Announces the First Patient Enrolled in International Afib Study
12.17.2015
The collaborative study is the first international prospective
randomized multicenter study of its kind
WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 17, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced the first
patient has been enrolled in the CEASE (Combined
Endoscopic Epicardial
and Percutaneous)
AF clinical study.
The CEASE AF study will compare the results of a combined epicardial
surgical plus endocardial catheter technique versus a standard
endocardial catheter ablation technique ...AtriCure to Present at the Piper Jaffray Healthcare Conference
11.23.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 23, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the Piper Jaffray Healthcare
Conference at the Palace Hotel in New York City on Tuesday, December 1,
2015. Management is scheduled to present at 10:30 a.m. Eastern Time. A
live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure Announces Upcoming Investor Conference Schedule
10.29.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the Stifel Healthcare Conference at
the Palace Hotel in New York City on Wednesday, November 18, 2015.
Management is scheduled to present at 2:15 p.m. Eastern Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
At...AtriCure Reports Third Quarter 2015 Financial Results
10.27.2015
Revenue of $31.4 million – up 17.8% as reported, 20.6% constant
currency
U.S. sales of $24.7 million – up 23.0%
International sales of $6.7 million – up 2.1% as reported, 13.2%
constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 27, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced third quarter 2015 financial results.
“We are pleased with our performance in the third quarter and excited
about our prospects for sustained growth,” said Mike Carrel, Pre...AtriCure Completes Acquisition of nContact
10.13.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 13, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
completed its previously announced acquisition of nContact, Inc., a
privately held developer of innovative cardiac ablation solutions.
About AtriCure
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System ...AtriCure to Announce Third Quarter 2015 Financial Results
10.08.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 8, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, will
release its financial results for the third quarter of 2015 on Tuesday,
October 27, 2015.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, October 27, 2015 to discuss its third quarter 2015 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (855)...AtriCure Enters Into Definitive Agreement to Acquire nContact
10.04.2015
Announces Preliminary Results for Third Quarter 2015, Updates Outlook
for 2015 and Provides 2016 Outlook
Company to Host Conference Call Monday, October 5 at 8:30am ET
Acquisition expands available market opportunity
Complementary
product lines to provide additional solutions for serious forms of
Atrial Fibrillation
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 4, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
entered into a definitive merger agreement under which AtriCure...AtriCure Announces Launch of the cryoFORM™ Cryoablation Probe
09.30.2015
Offering expands on the company’s cryoablation suite of products by
introducing an even more flexible probe for use in a variety of surgical
interventions to treat cardiac arrhythmias
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 30, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced the launch
of the cryoFORM™ cryoablation probe, which offers increased probe
flexibility to adapt to a variety of surgical ablation procedures. This
offering adds to the cryoICE™ family of ablation products which are used
in the cry...AtriCure to Present at the Morgan Stanley Global Healthcare Conference
08.21.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Aug. 21, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Morgan Stanley Global
Healthcare Conference at the Grand Hyatt Hotel in New York City on
Friday, September 18, 2015. Management is scheduled to present at 10:30
a.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at www.atricure.com.
A replay of the presentation will be available for 90 days following the
pre...AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
07.28.2015
Revenue of $32.6 million – up 22.9% as reported, 26.5% constant
currency
U.S. sales of $25.7 million – up 29.3%
International sales of $6.8 million – up 3.5% as reported, 17.9%
constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 28, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for
the surgical treatment of atrial fibrillation and left atrial appendage
management, today announced second quarter 2015 financial results.
“We are pleased by our results this quarter which reflect continued
stability in our business and the solid foun...AtriCure to Present at the Canaccord 35th Annual Growth Conference
07.15.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Canaccord 35th
Annual Growth Conference at the Intercontinental Hotel in Boston on
Wednesday, August 12, 2015. Management is scheduled to present at 1:00
p.m. Eastern Time. A live audio webcast of the presentation may be
accessed by visiting the Investors page of AtriCure’s corporate website
at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentati...AtriCure to Announce Second Quarter 2015 Financial Results
07.07.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 7, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for
the surgical treatment of atrial fibrillation and left atrial appendage
management, will release its financial results for the second quarter of
2015 on Tuesday, July 28, 2015.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, July 28, 2015 to discuss its second quarter 2015 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator...AtriCure to Present at the JMP Securities Life Sciences Conference
06.02.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 2, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the JMP Securities Life Sciences
Conference at the St. Regis in New York on Wednesday, June 24, 2015.
Management is scheduled to present at 9:00 a.m. Eastern Time. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
Ab...AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
04.29.2015
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency
U.S. sales of $22.9 million – up 26.3%
International sales of $7.0 million – up 3.9% as reported, 17.6%
constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for
the surgical treatment of atrial fibrillation and left atrial appendage
management, today announced first quarter 2015 financial results.
“We had a strong start to the year and remain well positioned to help
treat patients suffering from atrial fibrillation thro...AtriClip System Surpasses 50,000 Units Sold Worldwide
04.21.2015
AtriClip is the most widely used device globally for left atrial
appendage management
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced it has sold more than 50,000 AtriClip® Left Atrial
Appendage Exclusion System devices worldwide, making it not only the
preferred surgical device but also the most widely used of all devices
for excluding the left atrial appendage (LAA), with more units sold than
all other LAA management devices combined.
...AtriCure to Announce First Quarter 2015 Financial Results
04.08.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for
the surgical treatment of atrial fibrillation and left atrial appendage
management, will release its financial results for the first quarter of
2015 on Wednesday, April 29, 2015.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Wednesday, April 29, 2015 to discuss its first quarter 2015 financial
results. A live webcast of the conference call will be available online
on the Investor page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an oper...AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
04.07.2015
Fellowship provides newly graduated cardiothoracic surgeons with a
unique opportunity to be trained by nationally recognized experts in
atrial fibrillation surgery
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in technologies for the surgical
treatment of atrial fibrillation (Afib) and left atrial appendage
management, together with the American Association for Thoracic Surgery
(AATS) Graham Foundation has announced the inaugural James L. Cox
Fellowship in Atrial Fibrillation Surgery.
The multi-year commitment will provide newly graduated cardiotho...AtriCure to Present at the Needham Healthcare Conference
03.25.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Needham Healthcare
Conference at the Westin Grand Central Hotel in New York on Tuesday,
April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern
Time. A live audio webcast of the presentation may be accessed by
visiting the Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
...AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
03.18.2015
The CryoICE® cryo ablation probe is now available for cryoanalgesia
therapy
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in technologies for the surgical
treatment of atrial fibrillation (Afib) and left atrial appendage
management, today announced that it has launched the availability of its
cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for
temporary pain management. AtriCure’s cryoICE is the first FDA cleared
cryo ablation probe for the treatment of cardiac arrhythmias and for the
temporary ablation of peripheral nerves to block pain.
...AtriCure Announces 2015 Analyst & Investor Meeting
03.05.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
will host an analyst and institutional investor meeting on Tuesday,
March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00
a.m. Eastern Time. The meeting will include remarks from the AtriCure
management team highlighting the company’s strategy for executing on its
growth initiatives as well as guest speakers to provide clinical
perspective.
Guest speakers:
James L. Cox, M.D., cardiothoracic surge...AtriCure to Present at the Barclays Capital Global Healthcare Conference
03.03.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Barclays Capital Global
Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach,
Florida on Tuesday, March 10, 2015. Management is scheduled to present
at 8:30 a.m. Eastern Time. A live audio webcast of the presentation may
be accessed by visiting the Investors page of AtriCure’s corporate
website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
...First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
02.24.2015
The collaborative study between cardiac surgeons and
electrophysiologists to deliver innovative solutions and new treatment
options for Atrial Fibrillation
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in technologies for the surgical
treatment of atrial fibrillation (Afib) and left atrial appendage
management, today announced the first two patients have been enrolled and
treated at PinnacleHealth CardioVascular Institute in Harrisburg,
Pennsylvania, in the Dual Epicardial and Endocardial Procedure (DEEP)
clinical study. The pivotal study is the first of ...AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
02.23.2015
2014 revenue of $107.5 million – up 31.2%
2014 U.S. sales of $80.2 million – up 28.7%
2014 International sales of $27.3 million – up 39.2%; 39.8% constant
currency
Fourth quarter 2014 revenue of $29.4 million – up 34.4%
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced fourth quarter and full year 2014
financial results.
“Our fourth quarter and full year 2014 results reflect strong
...AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
02.02.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
will release its financial results for the fourth quarter and full year
2014 on Monday, February 23, 2015.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Monday, February 23, 2015 to discuss its fourth quarter and full year
2014 financial results. A live webcast of the conference call will be
available online from the investor relations page of AtriCure’s
corporate website at www.atricure.com.
You may also acces...AtriCure to Present at the Leerink Global Healthcare Conference
01.19.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Leerink Global Healthcare
Conference at the Waldorf Astoria Hotel in New York on Thursday,
February 12, 2015. Management is scheduled to present at 1:00 p.m.
Eastern Time. A live audio webcast and replay of the presentation will
be available for 30 days following the presentation on the Investors
page of AtriCure’s corporate website at www.atricure.com.
About AtriCure, Inc.
Atri...Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
01.14.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that Douglas Seith will assume the role of Chief
Operating Officer. Mr. Seith will now be responsible for all global
commercial organizations as well as education and clinical science
programs. The company also announced that Andy Wade has been promoted to
Senior Vice President and Chief Financial Officer.
Mr. Seith has over 25 years of cardiology and general surgery sales and
sales leadership experience and has served a...AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
01.12.2015
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 12, 2015--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage
Management (“LAAM”), today announced preliminary financial results for
fourth quarter and full year 2014 and issued 2015 financial guidance.
Preliminary and unaudited revenue for fourth quarter 2014 is expected to
be approximately $29.5 million, reflecting growth of approximately 34.6%
over the fourth quarter of 2013. Based on this preliminary estimate,
revenue from U.S. customers is expected to be $22.1 million, reflecting
growth of 35.1%...AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
11.03.2014
AtriCure will investigate a minimally invasive approach to treat
patients with persistent or long-standing persistent atrial fibrillation
who have failed antiarrhythmic drug therapy
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 3, 2014--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management (LAAM), today
announced it has received approval for an Investigational Device
Exemption from the U.S. Food and Drug Administration (FDA) to begin
enrollment in the Dual Epicardial and Endocardial Procedure (DEEP) clinical
trial. The DEEP tria...AtriCure Announces Upcoming Investor Conference Schedule
10.31.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage Management,
today announced that it will present at the Stifel Healthcare Conference
2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014.
Management is scheduled to present at 3:35 p.m. Eastern Time. A live
audio webcast and replay of the presentation will be available for 30
days following the presentation on the Investors page of AtriCure’s
corporate website at www.atricure.com.
AtriCure management is scheduled to present at t...AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
10.30.2014
Revenue of $26.7 million – up 32.4%
U.S. sales of $20.1 million – up 26.7%
International sales of $6.6 million – up 53.4%; 53.9% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage
Management (“LAAM”), today announced financial results for the third
quarter of 2014.
“We had a strong third quarter with momentum across all of our product
lines in both the U.S. and internationally. We continue to see
increasing ph...AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
10.09.2014
This is the largest study of its kind to evaluate surgical ablation
for the treatment of chronic Afib
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management (LAAM), today
announced enrollment in the ABLATE Post Approval Study (PAS) is complete.
As of October 3, 2014, the ABLATE PAS enrolled 365 patients at 40
hospitals across the United States. AtriCure expects to release
preliminary data from the study in about a year, with a complete report
expected to be published ...AtriCure to Announce Third Quarter 2014 Financial Results
10.03.2014
WEST CHESTER, Ohio, Oct. 3, 2014 (GLOBE NEWSWIRE) -- AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, will release its financial results for the third quarter of 2014 on Thursday, October 30, 2014.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, October 30, 2014 to discuss its third quarter 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure's corporate website at www.AtriCure.com. You may also access this call through an operator by calling (800) 510-0219 for domestic callers and (617) 614-3451 f...AtriCure Announces the Release of the AtriClip® FLEX
09.18.2014
Increased shaft flexibility allows a surgeon more maneuverability
within a patient’s unique anatomy when excluding the left atrial
appendage
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2014--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and Left Atrial Appendage Management (LAAM), today
announced the introduction of the AtriClip® FLEX, a new
device with a more flexible aluminum shaft that allows surgeons to
better maneuver within a patient’s particular anatomy.
The device is one of four products within the AtriClip Left Atrial
Appendage...AtriCure Announces Upcoming Investor Conference Schedule
07.29.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 29, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the Canaccord
Genuity 34th Annual Growth Conference at the Intercontinental
Hotel in Boston on Wednesday, August 13, 2014. Management is scheduled
to present at 8:30 a.m. Eastern Time. A live audio webcast and replay of
the presentation will be available for 30 days following the
presentation at http://wsw.com/webcast/canaccord14/atrc.
AtriCure management is also scheduled to participate in the Barrington
Research 7th Annual Fall Investment Confe...AtriCure Reports Second Quarter 2014 Financial Results and Updates 2014 Outlook
07.24.2014
Revenue of $26.5 million – up 29.8%
U.S. sales of $19.9 million – up 28.8%
International sales of $6.6 million – up 32.9%; 29.1% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 24, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”)
medical device provider, today announced financial results for the
second quarter of 2014.
“We are pleased with our performance in the second quarter in which we
delivered solid revenue growth while integrating Estech that further
positions us as a leader in the treatment of Afib. We also continued to
e...AtriClip® System Surpasses 34,000 Units Sold
07.16.2014
AtriClip is the most widely used device indicated for left atrial
appendage management
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 16, 2014--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib), today announced that it has sold more than 34,000
AtriClip® Left Atrial Appendage Exclusion System devices
worldwide, quickly becoming the top selling device used for eliminating
the left atrial appendage (LAA).
The LAA is a muscular pouch attached to the heart’s left atrium. In
patients with Afib and other cardiac arrhythmias, blood can pool and
form clot...AtriCure to Announce Second Quarter 2014 Financial Results
07.03.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 3, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, will release its financial results for the second
quarter of 2014 on Thursday, July 24, 2014.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, July 24, 2014 to discuss its second quarter 2014 financial
results. A live webcast of the conference call will be available online
from the investor relations page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (877)
703-6106 for domestic callers and (85...AtriCure to Present at the 9th Annual JMP Securities Healthcare Conference
05.28.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--May 28, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the 9th
Annual JMP Securities Healthcare Conference at The Westin New York Grand
Central on Tuesday, June 24, 2014. Management is scheduled to present
at 1:30 p.m. Eastern Time.
A live audio webcast and replay of the presentation will be available
for 90 days following the presentation at http://wsw.com/webcast/jmp24/ATRC.
About AtriCure, Inc.
AtriCure,
Inc. is a medical device company providing innovative atrial
fibrillation (Afib)...AtriCure Announces First Patient Enrolled in Stroke Feasibility Study
05.21.2014
First U.S. clinical study to evaluate the safety of a novel
epicardial-based left atrial appendage closure device for stroke
prevention in atrial fibrillation patients.
WEST CHESTER, Ohio--(BUSINESS WIRE)--May 21, 2014--
AtriCure,
Inc. (Nasdaq:
ATRC), a leader in surgical solutions to treat atrial fibrillation
(Afib), today announced the first patient enrolled in a feasibility
study using the AtriClip® Left Atrial Appendage Exclusion System for
stroke reduction in Afib patients unable to take anticoagulation. Dr.
Marc Gerdisch, chief of cardiovascular and thoracic surgery at
Franciscan St. Francis Health in Indi...AtriCure Reports First Quarter 2014 Financial Results and Updates 2014 Outlook
04.24.2014
Revenue of $24.8 million – up 27.9%
U.S. sales of $18.1 million – up 23.9%
International sales of $6.7 million – up 39.9%; 36.4% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 24, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”)
medical device provider, today announced financial results for the first
quarter of 2014.
“We are off to a strong start in 2014, as our commitment to training and
education, clinical trial support and innovation continue to pay
dividends. We are seeing increasing physician interest in treating
patients ...AtriCure to Announce First Quarter 2014 Financial Results
04.04.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 4, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, will release its financial results for the first
quarter of 2014 on Thursday, April 24, 2014.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, April 24, 2014 to discuss its first quarter 2014 financial
results. A live webcast of the conference call will be available online
from the investor relations page of AtriCure’s corporate website at www.atricure.com.
You may also access this call through an operator by calling (866)
271-6130 for domestic callers...AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference
02.28.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the Cowen and
Company 34th Annual Health Care Conference at the Boston
Marriott Copley Place on Wednesday, March 5, 2014. Management is
scheduled to present at 9:20 a.m. Eastern Time.
A live audio webcast and replay of the presentation will be available
for 30 days following the presentation at www.atricure.com.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) s...AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results
02.27.2014
2013 revenue of $81.9 million – up 16.6%
2013 U.S. sales of $62.3 million – up 18.4%
Fourth quarter revenue of $21.9 million – up 19.2%
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 27, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”)
medical device provider, today announced fourth quarter and full year
2013 financial results.
“We are pleased with our team’s performance in 2013 and momentum as we
move into 2014. Our commitment to training and education, clinical trial
support and innovation, coupled with our strategic acquisition of
Estech, pos...AtriCure Prices Public Offering of Common Stock
02.13.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 13, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced the pricing of its previously announced
underwritten public offering of 4,250,000 shares of its common stock at
a public offering price of $19.25 per share. AtriCure is offering
3,023,025 shares and selling stockholders are offering 1,226,975 shares
of common stock. In connection with the offering, AtriCure has also
granted the underwriter a 30-day option to purchase up to an additional
637,500 shares of common stock to cover over-allotments, if any.
Net proceeds from t...AtriCure Announces Commencement of Public Offering of Common Stock
02.12.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 12, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that AtriCure and certain selling
stockholders intend to offer shares of AtriCure common stock in a public
offering. AtriCure also expects to grant the underwriters a 30-day
option to purchase additional shares of its common stock to cover
over-allotments, if any. AtriCure plans to use the net proceeds from the
offering for general corporate purposes and working capital. AtriCure
will not receive any proceeds from the sale of common stock by the
selling stockholders.
...AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results
02.04.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, will release its financial results for the fourth
quarter and full year 2013 on Thursday, February 27, 2014.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Thursday, February 27, 2014 to discuss its fourth quarter and full year
2013 financial results. A live webcast of the conference call will be
available online from the investor relations page of AtriCure’s
corporate website at www.atricure.com.
Pre-registration is available and recommended for this call at ...AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference
01.20.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the Leerink
Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in
New York on Wednesday, February 12, 2014. Management is scheduled to
present at 11:30 a.m. Eastern Time.
A live audio webcast and replay of the presentation will be available
for 30 days following the presentation at www.atricure.com.
About AtriCure, Inc.
AtriCure,
Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solu...AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance
01.09.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 9, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced preliminary financial results for
fourth quarter and full year 2013 and issued 2014 financial guidance.
Preliminary revenue for the fourth quarter of 2013 is expected to be
approximately $21.9 million, reflecting growth of approximately 19% over
the fourth quarter of 2012. Based on this preliminary estimate, revenue
from U.S. customers is expected to be $16.4 million, reflecting growth
of 20%, and revenue from international customers is expected to be $5.5
million, refle...AtriCure Completes Acquisition of Estech
01.02.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 2, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical
device provider, today announced the completion of the previously
announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech
(“Estech”). Estech develops and markets a portfolio of innovative
surgical ablation devices that enable physicians to perform a variety of
traditional and minimally invasive procedures using Estech’s proprietary
temperature controlled RF energy.
“We are pleased to complete the acquisition of Estech, and we welcome
the team to AtriCure. This transaction provides substantia...AtriCure Announces Definitive Agreement to Acquire Estech
12.19.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 19, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation (Afib)
medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech
(“Estech”), today announced that they have entered into a definitive
merger agreement under which AtriCure has agreed to acquire Estech for a
cash-free, debt-free up-front payment of approximately 2.1 million
shares or $34 million of AtriCure common stock and up to $26 million in
additional consideration based on the achievement of certain
revenue-based milestones. The transaction is subject to customary
closing conditions and is expected t...AtriCure Receives FDA Approval for Investigational Study to Evaluate Stroke Prevention in Atrial Fibrillation
11.19.2013
AtriClip™ Left Atrial Appendage Exclusion System to be Evaluated
as Alternative to Anti-Coagulation Therapy
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 19, 2013--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading developer of solutions to treat atrial fibrillation
(Afib), today announced the Food and Drug Administration’s (FDA)
approval to begin enrollment in a clinical study of AtriCure’s AtriClip®
Left Atrial Appendage Exclusion System. The study will evaluate the use
of the AtriClip device to prevent stroke in patients with Afib.
The feasibility study will enroll Afib patients at seven medical centers
across the...AtriCure Announces Upcoming Investor Conference Schedule
10.31.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical
device provider, today announced that it will be participating in the
following upcoming investor conferences:
The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at
the Westin Grand Central Hotel in New York on November 14, 2013.
The Piper Jaffray 2013 Annual Health Care Conference at the New York
Palace Hotel on December 4, 2013.
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner,
providin...AtriCure Reports Third Quarter 2013 Financial Results
10.29.2013
Revenue of $20.1 million – up 24.8%; 24.0% constant currency
U.S. sales of $15.8 million – up 28.1%
International sales of $4.3 million – up 14.2%; 10.8% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical
device provider, today announced financial results for the third quarter
of 2013.
“We are pleased with our performance in the third quarter. Our results
reflect our third consecutive quarter of double digit year over year
revenue growth, driven by overall strength and our U.S. business ...AtriCure to Announce Third Quarter 2013 Financial Results
10.07.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 7, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions
partner providing innovative products, professional education and
support for clinical science to reduce the economic and social burden of
atrial fibrillation, will release its financial results for the third
quarter of 2013 on Tuesday, October 29, 2013.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on
Tuesday, October 29, 2013 to discuss its third quarter 2013 financial
results. A live webcast of the conference call will be available online
from the investor relations page of AtriCur...Health Risks of Atrial Fibrillation Raised During Awareness Month
09.19.2013
AtriCure Seeks to Improve Lives by Encouraging Education and
Treatment for People with Afib
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 19, 2013--
September is Atrial Fibrillation (Afib) Awareness Month and AtriCure,
Inc. (Nasdaq:
ATRC) encourages those who are affected to participate in “ACT
Against Afib,” a new campaign focused on raising awareness of the risks
of Afib and the various treatment options available. AtriCure is a
leading developer of medical devices used in the treatment of Afib and
offers the only FDA-approved device for the surgical treatment of Afib.
“ACT” is an acronym used to communicate the ...AtriCure Announces Commitment to Improve Lives of 250,000 Atrial Fibrillation Patients
09.18.2013
Investment in Clinical Studies, Education to Advance New Technology
Brings Hope to Patients Suffering from Afib
WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2013--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading atrial fibrillation (Afib) solutions partner, has
announced a significant multi-year strategic investment in clinical
trial and educational initiatives aimed at reducing the global Afib
epidemic. The announcement coincides with Atrial Fibrillation Awareness
Month, which was created to bring attention to this growing public
health issue. Afib is associated with significant morbidity and
mortality from stroke an...International News
AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
08.28.2018
Landmark study is the first prospective, randomized study comparing
the Convergent approach to endocardial catheter ablation in persistent
and long-standing persistent atrial fibrillation patients
MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has completed enrollment of the full
cohort of 153 patients in the CONVERGE IDE clinical trial.
The CONVERGE IDE trial is a landmark prospective, randomized trial
underway in the United States comparing the Convergent ap...AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
06.05.2018
Baheal will serve as the exclusive distribution partner for AtriCure
products across China
MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has partnered with Baheal Pharmaceutical
Group in China to distribute AtriCure’s surgical ablation devices. This
new multi-year agreement establishes Baheal as the exclusive distributor
for AtriCure, and replaces the company’s previous distributor in China.
“We are pleased to have formed this new partnership with Baheal,” sai...AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
04.25.2017
AtriClip is the most widely used device globally for left atrial
appendage management
MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage management, today
announced it has sold more than 100,000 AtriClip® Left Atrial
Appendage Exclusion System devices worldwide, which makes it the most
widely used of all devices for excluding the left atrial appendage (LAA).
“The AtriClip franchise is one of the fastest growing parts of our
business and is a meaningful driver of our broadening pre...AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
03.14.2017
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced that it has named Dr. David B. DeLurgio as
the national principal investigator (PI) for the CONVERGE IDE clinical
trial.
Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in
Atlanta, GA. He is Director of Electrophysiology at the Emory Heart and
Vascular Center at Emory St. Joseph’s Hospital, a role he has served in
since 2014. Dr. DeLurgio earned his medical degree from the University
of Californi...AtriCure Announces Approval for the cryoICE™ Platform in Japan
11.01.2016
Approval adds to the growing portfolio of AtriCure products now
available in the Japanese market
MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it has received approval from the Japanese Ministry of Health, Labor and
Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation probe.
The approval marks the first time that these products will be available
in the Japanese market.
“We are pleased to have this approval in hand, and to be able to bri...AtriCure Receives CE Mark for the AtriClip® PRO2 Device
06.29.2016
CE Mark brings the increased functionality of the AtriClip PRO2
device to the European market for use in managing the left atrial
appendage; product was launched in the U.S. in April 2016
MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that it has
received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA)
Exclusion System, which offers increased functionality to occlude the
LAA during minimally-invasive surgical (MIS) procedures. The device was
previously lau...AtriCure Announces Approval for the AtriClip in Japan
01.19.2016
Approval opens up a new market for the most widely implanted left
atrial appendage occlusion device in the world
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2016--
AtriCure,
Inc. (Nasdaq:
ATRC), a leading innovator in treatments for atrial fibrillation
(Afib) and left atrial appendage (LAA) management, today announced that
it has received approval from the Japanese Ministry of Health, Labor and
Welfare (MHLW) for its AtriClip™ products, which includes the AtriClip™
Standard and the AtriClip Pro™ devices.
“We are excited to bring the AtriClip to Japan,” said Mike Carrel,
President and CEO of AtriCure. “...In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
10.01.2013
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013--
AtriCure,
Inc. (Nasdaq:
ATRC), is partnering with leading atrial fibrillation (Afib) centers
and thought leaders across Europe to provide best-in-class training on
surgical ablation. The launch of an international Maze IV Training
program will take place on October 1 in Germany at Sana Stuttgart
Cardiac Surgery Center, one of six initial European hospitals selected
to participate in this important initiative. This initial course will be
led by surgeons recognized as experts in the field of surgical treatment
for Afib. They include:
James L. Co...Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
06.18.2013
Patients show three-year freedom from atrial fibrillation,
anti-arrhythmic drugs
PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013--
A leading German cardiovascular heart center reported promising mid-term
results for the surgical treatment of persistent atrial fibrillation
(Afib) during last week’s International Society for Minimally Invasive
Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech
Republic. At three-year follow-up, 80 percent of persistent Afib
patients were free from Afib and off anti-arrhythmic medications using
AtriCure’s Bipolar RF Ablation System. These results compare favorably
with a more comm...